GLP1R and metabolic dysfunction-associated steatohepatitis: Semaglutide, a GLP-1 receptor agonist, has been approved for the treatment of type II diabetes mellitus and obesity, yet its effects on the hepatic manifestation of the metabolic syndrome, NAFLD-NASH, are less well recognized.